U.S. Markets open in 5 hrs 33 mins

Vertex enters Duchenne field with $245M buy of Exonics

Allison DeAngelis
Vertex enters Duchenne field with $245M buy of Exonics

Biotech giant Vertex Pharmaceuticals announced plans Thursday to acquire a Cambridge-based preclinical gene editing startup, giving a run for the money to fellow Cambridge drugmaker Sarepta Therapeutics and others developers of drugs for Duchenne muscular dystrophy.